Table 1. Characteristics of healthy volunteer cohorts after heterologous-, mRNA-, or vector-based vaccination.
The mRNA-based vaccine cohort includes healthy volunteers vaccinated two (complete vaccination) or three times (booster vaccination) with either mRNA-1273 or BNT162b2. Donors of the vector-based vaccine either received two doses of ChadOx1 (complete vaccination) or one dose of Ad26.COV2.S (complete vaccination). The heterologous vaccination group received one dose of ChadOx1 followed by one (complete vaccination) or two doses (booster vaccination) of either mRNA-1273 or BNT162b2. For mRNA- and heterologous-vaccinated donors, we analyzed two different time points after complete vaccination, the time point of complete vaccination 3 to 12 weeks after complete vaccination and the time point 6 months after complete vaccination (21 to 32 weeks after complete vaccination). Figures 1 to 3 show T cell responses after complete vaccination, and analysis over different time points is shown in Fig. 4. Figure 4 includes the identical results for the time point of complete vaccination for mRNA- and heterologous-vaccinated donors as shown in Figs. 1 to 3. Experiments were not always conducted with all donors, depending on available cell numbers. n, number; n.a., not applicable; CV, complete vaccination.
| mRNA vaccine cohort | Vector vaccine cohort | Heterologous vaccination cohort | |
|---|---|---|---|
| Number of donors | 35 | 10 | 17 |
| Age (years) | |||
| Median | 38 | n.a. | 31 |
| Range | 25–71 | n.a. | 24–52 |
| Sex [n (%)] | |||
| Female | 19 (54.3) | n.a. | 11 (64.7) |
| Male | 16 (45.7) | n.a. | 6 (35.3) |
| Comorbidities [n (%)] | |||
| High blood pressure | 3 (12.5) | n.a. | 1 (5.9) |
| Cardiovascular disease | 1 (4.2) | n.a. | 1 (5.9) |
| Blood sugar disorder | 2 (8.3) | n.a. | 0 (0.0) |
| Chronic lung disease | 0 (0.0) | n.a. | 1 (5.9) |
| Cancer disease | 1 (4.2) | n.a. | 0 (0.0) |
| n.a. | 11 | n.a. | 0 |
| Vaccination schemes (CV) | |||
| BNT162b2 x BNT162b2 | 20 (83.3) | ||
| mRNA-1273 x mRNA-1273 | 4 (16.7) | ||
| ChadOx1 x ChadOx1 | 6 (60.0) | ||
| Ad26.COV2.S | 4 (40.0) | ||
| ChadOx1 x BNT162b2 | 7 (46.7) | ||
| ChadOx1 x mRNA-1273 | 8 (53.3) | ||
| Time points | |||
| Prevaccination | |||
| Donors | – | – | 9 |
| After the first vaccination | |||
| Donors | – | – | 8 |
| Weeks after vaccination | |||
| Median | – | – | 10 |
| Range | – | – | 9–10 |
| After complete vaccination | |||
| Donors | 24 | 10 | 15 |
| Weeks after vaccination | |||
| Median | 3 | 4 | 6 |
| Range | 3–10 | 3–8 | 3–12 |
| Awareness of side effects [n (%)] | |||
| Yes | 9 (69.2) | n.a. | 5 (50.0) |
| No | 4 (30.8) | n.a. | 5 (50.0) |
| n.a. | 11 | n.a. | 5 |
| 6 months after complete vaccination | |||
| Donors | 11 | – | 17 |
| Weeks after vaccination | |||
| Median | 26 | – | 26 |
| Range | 21–32 | – | 24–28 |
| After booster vaccination | |||
| Donors | 13 | – | 17 |
| Weeks after vaccination | |||
| Median | 4 | – | 4 |
| Range | 2–7 | – | 3–6 |
| Awareness of side effects [n (%)] | |||
| Yes | 2 (18.2) | – | 6 (35.3) |
| No | 9 (81.8) | – | 11 (64.7) |
| n.a. | 2 | – | 0 |